Second-line treatment of advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 4, 2008, Pages 430-440

  Gridelli, Cesare ^a   Ardizzoni, Andrea ^b   Ciardiello, Fortunato ^c   Hanna, Nasser ^d   Heymach, John V ^e   Perrone, Francesco ^f   Rosell, Rafael ^g   Shepherd, Frances A ^h   Thatcher, Nick ⁱ   Vansteenkiste, Johan ^j   De Petris, Luigi ^k   Di Maio, Massimo ^l   De Marinis, Filippo ^m  

^a S G MOSCATI HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k KAROLINSKA INSTITUTE   (Sweden)

^l N Giannettasio Hospital   (Italy)

^m SAN CAMILLO FORLANINI HOSPITAL   (Italy)

more..

Author keywords

Docetaxel; Erlotinib; Non small cell lung cancer; Pemetrexed; Second line chemotherapy

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL POLIGLUMEX; PEMETREXED; PLACEBO; SUNITINIB; TOPOTECAN; VANDETANIB; VINFLUNINE;

ABDOMINAL PAIN; ANEMIA; ASIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 41749112477     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318168c815     Document Type: Article

References (68)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
2. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 1997;24:455-462.
3. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000;18:3722-3730.
4. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997;15:2996-3018.
5. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
6. Ettinger DS, Bepler G, Bueno R, et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:548-582.
7. Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2007;2:402-407.
8. Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25:1377-1382.
9. Weiss G, Rosell R, Fossella F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:453-460.
10. Murillo JR, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small-cell lung cancer. Oncologist 2006;11:1095-1099.
11. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with Non-Small-Cell Lung Cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2085-2103.
12. Fossella FV, DeVore R, Kerr RN, et al. for the TAX 320 Non-Small-Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with Non-Small Cell Lung Cancer previously treated with platinum - containing chemotherapy regimens. J Clin Oncol 2000;18:2354-2362.
13. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously based with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004;43:183-194.
14. Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness of docetaxel in the second-line treatment of non-small-cell lung cancer. Pharmacoeconomics 2004;22:581-589.
15. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002;20:1344-1352.
16. Hainsworth JD, Burris HA 3rd, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
17. Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer 2001;92:2158-2163.
18. Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004.
19. Gervais R, Ducolone A, Breton JL, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005;16:90-96.
20. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389-8395.
21. Camps C, Massuti B, Jimenez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006;17:467-472.
22. Lai CL, Tsai CM, Chiu CH, et al. Phase II randomized trial of tri-weekly versus day 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 2005;35:700-706.
23. Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129:840-842.
24. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
25. Cohen MH, Johnson JR, Wang JC, et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005;10:363-368.
26. Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:2800-2807.
27. Bonomi P, Paz-Ares L, Langer C, et al. Xyotax versus docetaxel for the second-line treatment of non small cell lung cancer: the STELLAR 2 phase III study. Lung Cancer 2005;49:S35.
28. Bennouna J, Breton JL, Tourani JM, et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 2006;94:1383-1388.
29. Krzakowski M, Douillard J, Ramlau R, et al. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:7511.
30. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004;292:470-484.
31. Takeda K, Negoro S, Tamura T, et al. Docetaxel versus docetaxel plus gemcitabine for second-line treatment of non-small cell lung cancer: results of a JCOG randomized trial (JCOG0104). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004:7034.
32. Wachters FM, Groen HJ, Biesma B, et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 2005;92:15-20.
33. Pectasides D, Pectasides M, Farmakis D, et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005;16:294-299.
34. Georgoulias V, Kouroussis C, Agelidou A, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 2004;91:482-488.
35. Georgoulias V, Agelidou A, Syrigos K, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 2005;93:763-769.
36. Ciardiello F, De Vita F, Orditura M, Tortora G. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2004;16:130-135.
37. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
38. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2007;24:3831-3837.
39. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-6421.
40. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839, Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
41. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet 2005;366:1527-1537.
42. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol 2006;7:499-507.
43. Niho S, Ichinose Y, Tamura T, et al. Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:LBA7509.
44. Douillard JY, Kim ES, Hirsh V, et al. Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have previously received platinum-based chemotherapy (INTEREST). Eur J Cancer Supplements 2007;6:2.
45. Freidlin B, Breathnach OS, Johnson BE. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2003;9:917-922.
46. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, June 16-19, 1998. Ann Oncol 1998;9:1047-1052.
47. Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors for survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7:389-394.
48. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042.
49. Tsao M-S, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-144.
50. Shepherd FA, Ding K, Sakurada A, et al. Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer patients treated with erlotinib in National Cancer Institute of Cancer. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:7571.
51. Clark GM, Zborowski DM, Culbertson JL, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small-cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006;1:837-846.
52. Lynch TJ, Bell DW, Sordella R, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. N Engl J Med 2004;350:2129-2139.
53. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
54. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
55. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-595.
56. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-2939.
57. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499-506.
58. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163.
59. Fidias P, Dakhil S, Lyss A, et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007:LBA7516.
60. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-4411.
61. Scagliotti GV. Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel? Nat Clin Pract Oncol 2006;3:294-295.
62. Paesmans M, Berghmans T, Sculier JP. Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent? Lung Cancer 2007;55:135-136.
63. Heymach JV, Nilsson M, Blumenschein G, et al. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 2006;12(14 Pt 2):4441s-4445s.
64. Lee D, Heymach JV. Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 2006;7:304-308.
65. Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 2007;8(suppl 2):S79-S85.
66. Fehrenbacher L, O'Neill V, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:7062.
67. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:7000.
68. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-4277.